NASDAQ · BOLD
Boundless Bio, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for BOLD: Nov 4, 2026
Boundless Bio, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.62.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · NASDAQ.com · Fintel- BNK Invest · Oct 21, 11:21 AM EDTWednesday 10/21 Insider Buying Report: BOLD, OWLSAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys. On Tuesday, Boundless Bio's, Kevin Tang, made a $349,593 buy of BOLD, purchasing 14
- RTTNews · Aug 24, 6:34 AM EDTBiotech Stocks At 52-Week Highs – ELOX, PRLD, ARGX, BOLD, CORT(RTTNews) – The following biotech stocks reached a 52-week high on August 21, 2026, as new trials continued enrolment and companies released positive clinical research data.
- BNK Invest · Jul 15, 10:39 AM EDTWednesday 7/15 Insider Buying Report: GLBS, BOLDAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys. On Monday, Globus Maritime's Director, Georgios Feidakis, made a $602,886 purchase
- BNK Invest · Jun 30, 1:43 PM EDTTuesday 6/30 Insider Buying Report: BOLD, HNRGAs the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys. At Boundless Bio, a filing with the SEC revealed that on Monday, Kevin Tang bought
- RTTNews · Jun 26, 10:33 AM EDTWeekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired(RTTNews) – This week, the biotech sector delivered a mix of FDA and EU approvals, strategic reorganizations, layoff, acquisitions, and late-stage clinical readouts across oncology, metabolic disease, neurology and immunology.
- RTTNews · Jun 23, 11:13 PM EDTTop Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment(RTTNews) – Today's top gainers include Boundless Bio, which is combining with privately held Serapha; Monopar, on track for an NDA submission of ALXN1840 for Wilson disease; Jade Biosciences, advancing its autoimmune disease pipeline; and Galectin Therapeutics, which has reached
- RTTNews · Jun 23, 9:33 AM EDTBoundless Bio And Serapha Bio Announce Merger And $230 Million Private Placement; Stock Up(RTTNews) – Boundless Bio, Inc. (BOLD) and Serapha Bio, Inc., a privately held biotechnology company developing an in vivo base-editing therapy for Alpha-1 Antitrypsin Deficiency (AATD), have entered into a definitive all-stock merger agreement that will combine the two companies
- RTTNews · Jun 23, 8:34 AM EDTBoundless Bio Merges Serapha Bio; Raise $230 Mln In Private Placement; Stock Down(RTTNews) – Boundless Bio, Inc. (BOLD) and Serapha Bio on Tuesday announced a definitive merger agreement under which Serapha Bio, Inc. will combine with Boundless Bio in an all-stock transaction.
- NASDAQ.com · Jun 23, 8:28 AM EDTPre-Market Most Active for Jun 23, 2026 : AIXI, BOLD, SPCX, SQQQ, TQQQ, NOK, TSLL, AMC, INFQ, QBTS, SMR, VICIThe NASDAQ 100 Pre-Market Indicator is down -891.64 to 29,455.44. The total Pre-Market volume is currently 279,838,318 shares traded.The following are the most active stocks for the pre-market session: XIAO-I Corporation (AIXI) is +0.2193 at $3.28, with 25,246,339 shares traded.
- RTTNews · Apr 20, 5:10 AM EDTBoundless Bio Presents BBI-940's Preclinical Breast Cancer Data At AACR,2026(RTTNews) – Boundless Bio (BOLD), a clinical-stage oncology company, announced that it will present preclinical data supporting its lead therapy (ecDTx), BBI-940,for select advanced or metastatic breast cancers at the American Association for Cancer Research (AACR) Annual Meeting
- Fintel · Mar 27, 12:47 AM EDTBoundless Bio (BOLD) Price Target Increased by 33.33% to 4.08The average one-year price target for Boundless Bio (NasdaqGS:BOLD) has been revised to $4.08 / share. This is an increase of 33.33% from the prior estimate of $3.06 dated February 21, 2026. The price target is an average of many targets provided by analysts.
- Zacks · Feb 13, 12:00 PM ESTBoundless Bio, Inc. (BOLD) Upgraded to Buy: Here's WhyBoundless Bio, Inc. (BOLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Boundless Bio, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.